Emerging therapies for treatment of multiple sclerosis

References

• SetoSCarreraCJKubotaMWassonDBCarsonDAMechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytesJ Clin Invest19857523783
   Web of Science ®Google Scholar
• SpurgeonSYuMPhillipsJDEpnerEMCladribine: Not just another purine analogue?Expert Opin Investig Drugs200918811691181
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSKoziolJAMcMillanRZyroffJThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A1996934171617208643695
   PubMed Web of Science ®Google Scholar
• RiceGPFilippiMComiGCladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study GroupNeurology20005451145115510720289
   PubMed Web of Science ®Google Scholar
• RomineJSSipeJCKoziolJAZyroffJBeutlerEA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians1999111135449893155
   PubMedGoogle Scholar
• SeronoECLARITY: A Phase III, randomized, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis NCT00213135
   Google Scholar
• ColesAJCompstonDASelmajKWAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med2008358767668818272891
   PubMed Web of Science ®Google Scholar
• HawkerKO’ConnorPFreedmanMSRituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trialAnn Neurol200966446047119847908
   PubMed Web of Science ®Google Scholar
• GenentechHLRPhase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with RRMS NCT00676715
   Google Scholar
• BielekovaBCatalfamoMReichert-ScrivnerSRegulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosisProc Natl Acad Sci U S A2006103155941594616585503
   PubMed Web of Science ®Google Scholar
• BielekovaBRichertNHowardTHumanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon betaProc Natl Acad Sci U S A2004101238705870815161974
   PubMed Web of Science ®Google Scholar
• BielekovaBHowardTPackerANEffect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosisArch Neurol200966448348919364933
   PubMed Web of Science ®Google Scholar
• VigliettaVBourcierKBuckleGJCTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trialNeurology2008711291792418794494
   PubMed Web of Science ®Google Scholar
• MehlingMBrinkmannVAntelJFTY720 therapy exerts differential effects on T cell subsets in multiple sclerosisNeurology200871161261126718852441
   PubMed Web of Science ®Google Scholar
• BrinkmannVFTY720 (fingolimod) in multiple sclerosis: Therapeutic effects in the immune and the central nervous systemBr J Pharmacol200915851173118219814729
   PubMed Web of Science ®Google Scholar
• NovartisTRANSFORMS FTY720. A 12-month study comparing the efficacy and safety of two doses of fingolimod versus interferon β-1a in patients with relapsing-remitting multiple sclerosis with optional extension phase NCT00340834
   Google Scholar
• GlaxoSmithKlineRandomised, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the MRI efficacy and the safety of six months’ administration of SB-683699 in subjects with relapsing-remitting multiple sclerosis NCT00395317
   Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• Teva Pharmaceutical IndustriesA multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis NCT00988052
   Google Scholar
• de JongRBezemerACZomerdijkTPvan de Pouw-KraanTOttenhoffTHNibberingPHSelective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarateEur J Immunol1996269206720748814248
   PubMed Web of Science ®Google Scholar
• WierinckxABreveJMercierDSchultzbergMDrukarchBVan DamAMDetoxication enzyme inducers modify cytokine production in rat mixed glial cellsJ Neuroimmunol20051661–213214315993952
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot studyEur J Neurol200613660461016796584
   PubMed Web of Science ®Google Scholar
• KornTMagnusTToykaKJungSModulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletionJ Leukoc Biol200476595096015328336
   PubMed Web of Science ®Google Scholar
• Sanofi-AventisLong-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses NCT00803049
   Google Scholar
• Sanofi-AventisA randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis NCT00475865
   Google Scholar
• Sanofi-AventisA randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis NCT00489489
   Google Scholar
• Sanofi-AventisAn international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis NCT00622700
   Google Scholar
• Eli Lilly and CompanyAn open label follow-on study to assess the ongoing safety of MBP8298 in subjects with secondary progressive multiple sclerosis NCT00870155
   Google Scholar
• Eli Lilly and CompanyA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis NCT00869726
   Google Scholar
• CentocorIA Phase II, double-blind, placebo-controlled, randomized, dose-ranging study of multiple subcutaneous injections of human monoclonal antibody to IL-12 p40 (CNTO1275) in subjects with relapsing-remitting multiple sclerosis NCT00207727
   Google Scholar
• SeronoEMDAn open-label, multicenter Phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in subjects with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension) NCT00853762
   Google Scholar
• KarnezisTMandemakersWMcQualterJLThe neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelinationNat Neurosci20047773674415184901
   PubMed Web of Science ®Google Scholar
• LiebscherTSchnellLSchnellDNogo-A antibody improves regeneration and locomotion of spinal cord-injured ratsAnn Neurol200558570671916173073
   PubMed Web of Science ®Google Scholar
• FontouraPHoPPDeVossJImmunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitisJ Immunol2004173116981699215557195
   PubMed Web of Science ®Google Scholar
• MiSMillerRHLeeXLINGO-1 negatively regulates myelination by oligodendrocytesNat Neurosci20058674575115895088
   PubMed Web of Science ®Google Scholar
• LeeXYangZShaoZNGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelinationJ Neurosci200727122022517202489
   PubMed Web of Science ®Google Scholar
• SatohJTabunokiHYamamuraTArimaKKonnoHTROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesionsNeuropathol Appl Neurobiol20073319910717239012
   PubMed Web of Science ®Google Scholar
• MiSMillerRHTangWPromotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cellsAnn Neurol200965330431519334062
   PubMed Web of Science ®Google Scholar
• RafeiMCampeauPMAguilar-MahechaAMesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent mannerJ Immunol2009182105994600219414750
   PubMed Web of Science ®Google Scholar
• PluchinoSQuattriniABrambillaEInjection of adult neurospheres induces recovery in a chronic model of multiple sclerosisNature2003422693368869412700753
   PubMed Web of Science ®Google Scholar
• Hadassah Medical OrganizationExplorative trial to investigate the migration ability of mesenchymal bone marrow stem cells (MSC) in the central nervous system (CNS) following their intrathecal administration in severe cases of multiple sclerosis (MS) NCT00781872
   Google Scholar
• The Cleveland Clinic and University Hospital Case Medical CenterA Phase I study to assess the feasibility, safety, and tolerability of autologous mesenchymal stem cell transplantation in patients with relapsing forms of multiple sclerosis NCT00813969
   Google Scholar